About: An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) protein

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) protein Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) protein
Creator	Haghpanah, Vahid Cohan, Reza Ghafouri, Fatemeh Samimi, Hilda
Source	Medline; PMC
abstract	Since the first appearance of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- CoV-2) in China on December 2019, the world has now witnessed the emergence of the SARS- CoV-2 outbreak. Therefore, due to the high transmissibility rate of virus, there is an urgent need to design and develop vaccines against SARS-CoV-2 to prevent more cases affected by the virus. In this study, a computational approach is proposed for vaccine design against the envelope (E) protein of SARS-CoV-2, which contains a conserved sequence feature. First, we sought to gain potential B-cell and T-cell epitopes for vaccine designing against SARS-CoV-2. Second, we attempted to develop a multi-epitope vaccine. Immune targeting of such epitopes could theoretically provide defense against SARS-CoV-2. Finally, we evaluated the affinity of the vaccine to major histocompatibility complex (MHC) molecules to stimulate the immune system response to this vaccine. We also identified a collection of B-cell and T-cell epitopes derived from E proteins that correspond identically to SARS-CoV-2 E proteins. The in-silico design of our potential vaccine against E protein of SARS-CoV-2 demonstrated a high affinity to MHC molecules, and it can be a candidate to make a protection against this pandemic event.
has issue date	2020-05-20(xsd:dateTime)
bibo:doi	10.21203/rs.3.rs-30374/v1
bibo:pmid	32702713
has license	cc-by
sha1sum (hex)	970b8019f3eb3ff53c588e3e754924326fc03a65
schema:url	https://doi.org/10.21203/rs.3.rs-30374/v1
resource representing a document's title	An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) protein
has PubMed Central identifier	PMC7336711
has PubMed identifier	32702713
schema:publication	Res Sq
resource representing a document's body	covid:970b8019f3eb3ff53c588e3e754924326fc03a65#body_text
is schema:about of	named entity 'transmissibility' named entity 'protein' named entity 'China' named entity 'vaccine design' named entity 'SARS-CoV-2 outbreak' named entity 'epitopes' named entity 'SARS-CoV-2' named entity 'epitope' named entity 'MCP1' named entity 'epitopes' named entity 'protein structures' named entity 'protein' named entity 'WHO' named entity 'secondary response' named entity 'T-cell receptors' named entity 'peptides' named entity 'solubility' named entity 'peptides' named entity 'biological activities' named entity 'alleles' named entity 'HLA-B' named entity 'antibodies' named entity '2.0' named entity 'toxicity' named entity 'chimeric' named entity 'PEP' named entity 'epitopes' named entity 'epitopes' named entity 'pathogen' named entity 'chimeric' named entity 'conformations' named entity 'allergen' named entity 'I-TASSER' named entity 'machine learning' named entity 'B-cell' named entity 'alleles' named entity 'Peptide' named entity 'evolution' named entity 'transcriptomics' named entity 'epitopes' named entity 'peptide' named entity 'protein microarray' named entity 'phylogeny' named entity 'vaccine' named entity 'nucleocapsid' named entity 'epitopes' named entity 'FASTA' named entity 'homology modeling' named entity 'SARS-CoV-2' named entity 'protein' named entity 'epitopes' named entity 'isoelectric point' named entity 'conformations' named entity 'Coronaviridae' named entity '30 hours' named entity 'peptide' named entity 'cholera toxin' named entity 'MHC' named entity 'protein' named entity 'structural protein' named entity 'antigenicity' named entity '1,000,000' named entity 'Crystal structure' named entity 'MIP1A' named entity 'Allergen' named entity 'I-TASSER' named entity 'epitopes' named entity 'cytokines' named entity 'non-toxic' named entity 'Protein sequences' named entity 'isoelectronic' named entity 'peptide' named entity 'B-cell' named entity 'protein' named entity 'Vaccines' named entity 'UCSF Chimera' named entity 'psipred' named entity 'B-cell'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software